FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 336:1187-1189 April 17, 1997 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gill, P. S. PubMed Citation

To the Editor: Gill et al. (Oct. 24 issue)¹ reported that they induced apoptosis of two nodular cutaneous Kaposi's sarcoma lesions in each of 36 patients by administering human chorionic gonadotropin (hCG) intralesionally three times a week for two weeks; they noted that the efficiency of treatment was dose-dependent, with superior tumor responses in patients receiving 2000 IU per lesion as compared with those receiving 250, 500, or 1000 IU per lesion. As Krown stated in her editorial,² this treatment had a "limited and primarily cosmetic role," and there is no "evidence that uninjected lesions benefit."

Over the past several . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Malatos, S., Neubert, H., Kicman, A. T., Iles, R. K. (2005). Identification of Placental Transforming Growth Factor-{beta} and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques. Mol. Cell. Proteomics 4: 984-992 [Abstract] [Full Text]  
• Butler, S. A., Iles, R. K. (2003). Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection?. Clin. Cancer Res. 9: 4666-4673 [Abstract] [Full Text]